Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640985 | 0.80 | NOS3 (0.52) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL1161577 | 0.80 | MYC (0.39) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL2642690 | 0.80 | LOXL2 (0.52) | MYCXDHABCG2LOXLOXL2 | |
| SCHEMBL2642689 | 0.80 | MYC (0.39) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL454924 | 0.80 | RECQL (0.52) | MYCXDHABCG2PARP14KIT | |
| SCHEMBL131827 | 0.80 | MYC (0.39) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL451724 | 0.80 | MYC (0.39) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL3302943 | 0.80 | NOS3 (0.52) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL6466230 | 0.80 | MYC (0.39) | MYCXDHABCG2GRM5PARP14 | |
| SCHEMBL29631080 | 0.80 | MYC (0.39) | MYCXDHABCG2GRM5PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166177-A | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020070651-A1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | ABBVIE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | MYC 4811/4885XDH 141/4885ABCG2 2729/4885 |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | MYC 4149/4885XDH 888/4885ABCG2 890/4885 |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | MYC 266/4885XDH 2817/4885ABCG2 3924/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | MYC 3769/4885XDH 1516/4885ABCG2 3114/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | MYC 3710/4885XDH 1852/4885ABCG2 2800/4885 |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | MYC 4626/4885XDH 48/4885ABCG2 2324/4885 |
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | MYC 4572/4885XDH 1211/4885ABCG2 3441/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | MYC 1916/4885XDH 1347/4885ABCG2 2581/4885 |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | MYC 4626/4885XDH 48/4885ABCG2 2324/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | MYC 4626/4885XDH 48/4885ABCG2 2324/4885 |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PDE4A, PDE4B, PDE12 | MYC 4853/4885XDH 77/4885ABCG2 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.